Meta-analyses of transcriptomic data revealed that chemokine (C-X-C module) ligand 13 (CXCL13) within the CXCL9 module of the chemosensitive (pCR) model (Supplementary Figure S5) is one of the most robust predictors of favorable disease outcome for breast cancer patients treated with neoadjuvant chemotherapy (41). Here, CXCL13 is linked to breast cancer.